24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness

Learn more about:
Related Clinical Trial
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss Anti-Androgen Treatment for COVID-19 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss The Effect of Platelet Rich Plasma on Non-scarring Alopecia Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter HairDx Analytical Validation Study The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study To Evaluate the Pharmacokinetics and Safety of AD-208 The Utility of Platelet Rich Plasma in Hair Loss Computer-Assisted Versus Manual Hair Harvest Comparative Study Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) PAI-1 Expression in Non-scarring Hair Loss Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Cold Plasma to Treat Hair Loss Adipose-derived SVF for Treatment of Alopecia Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Photosensitization Study in Androgenetic Alopecia Point-of-Care Adipose-derived Cells for Hair Growth Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Modulated Light Therapy in Participants With Pattern Hair Loss Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia N-Acetyl-Cysteine for Treatment of AGA in Men Clinical Trial in Females for Female Pattern Hair Loss Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Treatment of Androgenetic Alopecia in Males and Females Microarray Analysis of Scalp Biopsies After Minoxidil Treatment Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis 24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Minoxidil Response Testing in Males With Androgenetic Alopecia Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Treatment of Androgenetic Alopecia in Females, 9 Beam Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Treatment of Androgenetic Alopecia in Males Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Treatment of Androgenetic Alopecia in Females, 12 Beam Nanofat Grafting for Treatment of Androgenetic Alopecia Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Treatment of Androgenic Alopecia in Males A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Androgenetic Alopecia and the JAK-STAT Pathway Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Brief Title

24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness

Official Title

A Randomized, Double -Blind,, Sham-Device-Controlled, Multicenter, 24-Week Clinical Trial to Evaluate the Safety and Effectiveness of the iRestore ™ Hair Rejuvenation System in the Treatment of Male and Female Androgeneticalopecia

Brief Summary

      The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation
      System when used as directed in promoting hair growth in men and women with androgenetic
      alopecia
    

Detailed Description

      The test treatment is the iRestore™ Hair Rejuvenation System. The device irradiates the scalp
      with visible light using 5 mW (class 3a) lasers. It is to be used approximately 3 times per
      week for approximately 30 minutes at each session.

      The System is placed on the head and adjusted to a comfortable size by rotating knobs on the
      side of the device. If needed, subjects may replace the soft pad on the inside of the device
      with the thinner pad provided. There will be 2 options for using the product. The subject
      will either insert the 5-V AC power adapter pin into the device remote control, and the 5-V
      adapter will then be plugged into the AC outlet; or the subjects will use the rechargeable
      battery pack and belt clip. The battery pack is an external device which will allow the
      subject the freedom of mobility while treating the hair. The rechargeable battery pack will
      hold a charge for up to 3 hours prior to needing to be recharged. The iRestore™ remote
      control clips into the battery holster and the pack plugs into the remote. The battery pack
      can be placed in a pocket, clipped to the belt or placed next to the subject. The device will
      be turned on by pressing the power button on the remote control. The dome of the device is to
      be moved forward and backward by the subject to brush through the hair and increase the
      direct light which comes into contact with the scalp. Subjects will then position the dome at
      the front of the scalp and press the start button to begin a 10-minute session. Note: As a
      safety feature, the dome must be placed onto the head prior to starting the device. A timer
      will indicate the completion of the session with a beep sound. Subjects will complete the
      same process as done with the front of the scalp with the dome repositioned to the middle of
      the scalp and then the back of the scalp. Once all 3 positions have received the 10 minute
      treatment, the power button is to be held for approximately 3 seconds to turn the device off.
      Once off the device is to be unplugged from the wall.

      The control device will be identical to the test device except that the laser-emitting units
      will be disabled. A standard light will be emitted from the device. Subjects and clinical
      staff engaged in the performance of assessments will be treatment blinded.
    


Study Type

Interventional


Primary Outcome

Change from Screening/Baseline Hair Growth at Week 12 and Week 24

Secondary Outcome

 Visual Scalp Assessment

Condition

Androgenetic Alopecia

Intervention

iRestore Hair Rejuvenation System

Study Arms / Comparison Groups

 iRestore Hair Rejuvenation System
Description:  Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Device

Estimated Enrollment

100

Start Date

July 2012

Completion Date

May 2013

Primary Completion Date

April 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Individuals eligible for inclusion in the study are those who:

               1. Are male or female, 25 to 60 years of age;

               2. If male, have Norwood-Hamilton classifications of IIa to V male pattern baldness;

               3. If female, have Ludwig Scale classifications I-4, II-1, II-2, or frontal;

               4. Are willing to have a tattoo created on the target area;

               5. Have been experiencing active hair loss within the last 12 months;

               6. In the case of females of childbearing potential, are using an acceptable form of
                  birth control (oral/implant/injectable/transdermal contraceptives, intrauterine
                  device, condom with spermicide, diaphragm with spermicide, abstinence or
                  partner's vasectomy: abstinence or partner's vasectomy are acceptable if the
                  female agrees to implement one of the other acceptable methods of birth control
                  if her lifestyle or partner changes);

               7. Have Fitzpatrick Skin Type I-IV (See Table 1 Below);

               8. Are willing to have the target area hair clipped;

               9. Read, understand, and sign a photographic release form(s); and

              10. Read, understand, and sign an informed consent document after being advised of
                  the nature of the study.

        Table 1: Fitzpatrick Skin Types I Always burns easily, never tans II Always burns easily,
        tans minimally III Burns moderately, tans gradually (light brown) IV Burns minimally,
        always tans well (moderate brown) V Rarely burns, tans very well (moderate brown) VI Never
        burn, deeply pigmented

        Exclusion Criteria:

          -  Individuals excluded from participation in the study are those who:

               1. Have used any of the following medications within 6 months prior to enrollment:

                    -  minoxidil, finasteride (or any other 5α-reductase inhibitor medications);

                    -  medications with anti-androgenic properties (eg, cyproterone,
                       spironolactone, ketoconazole, flutamide, and bicalutamide);

                    -  topical estrogens, progesterone, tamoxifen, anabolic steroids;

                    -  medications that can potentially cause hypertrichosis (eg, ciclosporin,
                       diazoxide, phenytoin, and psoralens);

                    -  oral glucocorticoids (inhaled glucocorticoids are permitted);

                    -  lithium or phenothiazines;

                    -  medications of known or suspected phototoxicity (eg, tetracyclines,
                       thiazides, certain NSAIDs);

                    -  other medications which, in the opinion of the investigator, may interfere
                       with the performance of study assessments or place the subject at undue
                       risk;

               2. Will not agree to refrain from changing hair color and hair style during the
                  course of the study;

               3. Have had a hair transplant, scalp reduction, hair weave, or tattoo which, in the
                  opinion of the investigator, may interfere with the performance of the study
                  assessments;

               4. Are using or have used depilatories, razors, or wax on the scalp to an extent
                  which, in the opinion of the investigator, may interfere with the performance of
                  the study assessments;

               5. Have psoriasis, active dermatitis/eczema, or severe acne on the scalp area;

               6. Have diabetes requiring exogenous insulin;

               7. Have cataracts;

               8. Have any medical condition which, in the opinion of the investigator, could
                  affect hair growth (eg, Human Immunodeficiency Virus, connective tissue disease,
                  inflammatory bowel disease);

               9. Have very little contrast between hair color and scalp, eg, are of a fair hair
                  color (eg, white or very blond) and have very pale skin;

              10. Are females who are pregnant, planning to become pregnant during the study, or
                  breastfeeding; and/or

              11. Are, in the opinion of the investigative personnel, unable to comprehend and/or
                  otherwise comply with any aspect of study requirements.
      

Gender

All

Ages

25 Years - 60 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Jonathan Dosik, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01686295

Organization ID

CS940112

Secondary IDs

CS940112

Responsible Party

Sponsor

Study Sponsor

Freedom Laser Therapy, Inc.

Collaborators

 TKL Research, Inc.

Study Sponsor

Jonathan Dosik, MD, Principal Investigator, TKL Research, Inc.


Verification Date

September 2012